Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed

Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.

Moving towards a new staging system for Parkinson’s

Cure Parkinson’s has been a part of a group of Parkinson’s scientists, charity organizations, and patient advocates from around the world to help develop a new biological staging framework for Parkinson’s.

Alpha-synuclein or Tau in Parkinson’s?

The build-up of a protein called alpha-synuclein has been considered one of the hallmarks of Parkinson’s. Recently, however, a group of scientists have called into question the ‘bad guy’ role of alpha-synuclein.

Exploring Perspectives on Trial Design for Parkinson’s: An Update on the Delphi Study

Recently, Cure Parkinson’s was pleased to see the results of one of our funded studies published in the Journal of Parkinson’s Disease.

A Review of Our 2023 Preclinical Projects

In 2023, Cure Parkinson’s has funded five new preclinical projects. These preclinical projects address a wide range of ‘targets’ to understand which drugs and which targets should be further tested in a clinical trial.